Review
doi: 10.1038/sj.leu.2401590.
Leukemogenesis by CBF oncoproteins
Affiliations
- PMID: 10602413
- DOI: 10.1038/sj.leu.2401590
Item in Clipboard
Review
Leukemogenesis by CBF oncoproteins
Leukemia.
1999 Dec.
Abstract
The AML1 and CBFbeta subunits of core binding factor (CBF) are involved in several chromosomal abnormalities frequently associated with acute leukemias. As a result, the CBFbeta-SMMHC, AML1-ETO and AML1-MDS1/EVI1 fusion proteins are expressed in subsets of acute myeloid leukemia, and TEL-AML1 is expressed in B-lineage acute lymphocytic leukemia. These CBF oncoproteins likely contribute to leukemogenesis in part by inhibiting endogenous CBF. As a result they are expected to inhibit differentiation and perhaps apoptosis. In addition, the domains unique to each fusion protein may also contribute to leukemogenesis via unique mechanisms.
Similar articles
-
The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.Blood. 1998 Mar 1;91(5):1688-99. Blood. 1998. PMID: 9473235
-
Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.Curr Top Microbiol Immunol. 1996;211:243-52. doi: 10.1007/978-3-642-85232-9_24. Curr Top Microbiol Immunol. 1996. PMID: 8585955
-
The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.Haematologica. 1997 May-Jun;82(3):364-70. Haematologica. 1997. PMID: 9234595 Review.
-
Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.Oncogene. 2000 May 18;19(22):2695-703. doi: 10.1038/sj.onc.1203588. Oncogene. 2000. PMID: 10851069
-
AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia.Leukemia. 2001 Apr;15(4):664-5. doi: 10.1038/sj.leu.2402035. Leukemia. 2001. PMID: 11368373 Review. No abstract available.
Cited by
-
Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1.PLoS Med. 2007 May;4(5):e172. doi: 10.1371/journal.pmed.0040172. PLoS Med. 2007. PMID: 17503961 Free PMC article.
-
Pathogenic Mechanisms in Acute Myeloid Leukemia.Curr Treat Options Oncol. 2022 Nov;23(11):1522-1534. doi: 10.1007/s11864-022-01021-8. Epub 2022 Oct 3. Curr Treat Options Oncol. 2022. PMID: 36190670 Review.
-
The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.PLoS One. 2019 Dec 23;14(12):e0226435. doi: 10.1371/journal.pone.0226435. eCollection 2019. PLoS One. 2019. PMID: 31869378 Free PMC article.
-
C/EBPα dysregulation in AML and ALL.Crit Rev Oncog. 2011;16(1-2):93-102. doi: 10.1615/critrevoncog.v16.i1-2.90. Crit Rev Oncog. 2011. PMID: 22150310 Free PMC article. Review.
-
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.Blood Rev. 2023 Jan;57:100996. doi: 10.1016/j.blre.2022.100996. Epub 2022 Aug 2. Blood Rev. 2023. PMID: 35989139 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
